Stocklytics Platform
Asset logo for symbol ARQT
Arcutis Biotherapeutics
ARQT46
$8.67arrow_drop_up4.27%$0.35
Asset logo for symbol ARQT
ARQT46

$8.67

arrow_drop_up4.27%
Key Stats
Open$8.45
Prev. Close$8.31
EPS-2.07
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.29
9.08
52 Week Range1.76
13.17
Ratios
EPS-2.07
Fundamentals
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ARQT-
US Healthcare Sector-
US Market-
check_circle

ARQT / Market

ARQT exceeded the US Market which returned 0.39% over the last twenty four hours.
check_circle

ARQT / Healthcare Sector

ARQT exceeded the US Healthcare sector which returned 3.96% over the last twenty four hours.

Arcutis Biotherapeutics (ARQT) Statistics

Arcutis Biotherapeutics Inc (ARQT) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for the treatment of dermatological conditions. The company's primary goal is to improve the lives of patients suffering from various skin diseases, including psoriasis, eczema, and alopecia areata.
With regards to ARQT's stock statistics, it is important to note that the company went public in July 2020, so its stock performance is relatively new. However, since its IPO, ARQT has shown promising results, with its stock price experiencing gradual growth. As of the latest available data, ARQT stock has outperformed the broader sector, indicating a positive market sentiment towards the company's prospects.
add Arcutis Biotherapeutics  to watchlist

Keep an eye on Arcutis Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Arcutis Biotherapeutics (ARQT) stock's performance compared to its sector and the market over the past year?

Over the past year, Arcutis Biotherapeutics (ARQT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 31.06%, Arcutis Biotherapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 72.87%, it has fallen short of the market average. This comparison highlights Arcutis Biotherapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Arcutis Biotherapeutics (ARQT) stock?

The PE ratio for Arcutis Biotherapeutics (ARQT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Arcutis Biotherapeutics (ARQT) stock?

The Earnings Per Share (EPS) for Arcutis Biotherapeutics (ARQT), calculated on a diluted basis, is -$2.07. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Arcutis Biotherapeutics (ARQT) stock?

The operating margin for Arcutis Biotherapeutics (ARQT) is -162.28%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Arcutis Biotherapeutics (ARQT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Arcutis Biotherapeutics (ARQT) is -$178.29M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Arcutis Biotherapeutics (ARQT) have?

Arcutis Biotherapeutics (ARQT) has a total debt of $207.56M. The net debt, which accounts for cash and cash equivalents against the total debt, is $122.68M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level